{
    "ticker": "IMTX",
    "name": "Immatics N.V.",
    "description": "Immatics N.V. is a clinical-stage biopharmaceutical company focused on the development of innovative T cell receptor (TCR) therapies for cancer treatment. Founded in 2000 and headquartered in T\u00fcbingen, Germany, Immatics leverages its proprietary XPRESIDENT\u00ae technology platform to identify and validate novel cancer targets. The company is dedicated to harnessing the power of the immune system to provide targeted and durable treatments for patients with various types of solid tumors. Immatics aims to address the significant unmet needs in oncology by developing therapies that can specifically recognize and eliminate cancer cells while sparing healthy tissue. Their lead product candidate, IMA201, is designed to treat patients with advanced solid tumors expressing specific target antigens. Immatics collaborates with leading academic institutions and pharmaceutical companies to advance its pipeline and enhance the understanding of cancer biology. By integrating cutting-edge science with deep clinical insights, Immatics strives to transform the treatment landscape for cancer patients and improve outcomes through precision medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "T\u00fcbingen, Germany",
    "founded": "2000",
    "website": "https://www.immatics.com",
    "ceo": "Harald Stock",
    "social_media": {
        "twitter": "https://twitter.com/Immatics",
        "linkedin": "https://www.linkedin.com/company/immatics-biotechnology/"
    },
    "investor_relations": "https://ir.immatics.com",
    "key_executives": [
        {
            "name": "Harald Stock",
            "position": "CEO"
        },
        {
            "name": "Klaus S. M. R. R. T. W. Gruber",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "T Cell Receptor Therapies",
            "products": [
                "IMA201",
                "IMA202"
            ]
        },
        {
            "category": "Pipeline",
            "products": [
                "IMA203",
                "IMA301"
            ]
        }
    ],
    "seo": {
        "meta_title": "Immatics N.V. | Innovative T Cell Receptor Therapies for Cancer",
        "meta_description": "Explore Immatics N.V., a leader in developing T cell receptor therapies for treating cancer. Learn about our innovative technology and pipeline.",
        "keywords": [
            "Immatics",
            "T Cell Receptor Therapy",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "Oncology",
            "Precision Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Immatics known for?",
            "answer": "Immatics is known for its innovative T cell receptor therapies designed for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of Immatics?",
            "answer": "Harald Stock is the CEO of Immatics N.V."
        },
        {
            "question": "Where is Immatics headquartered?",
            "answer": "Immatics is headquartered in T\u00fcbingen, Germany."
        },
        {
            "question": "What are Immatics' main products?",
            "answer": "Immatics' main products include T cell receptor therapies such as IMA201 and IMA202."
        },
        {
            "question": "When was Immatics founded?",
            "answer": "Immatics was founded in 2000."
        }
    ],
    "competitors": [
        "BMY",
        "NVS",
        "MRNA",
        "AMGN"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "GILD",
        "ABBV"
    ]
}